Compare WCN & BDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | WCN | BDX |
|---|---|---|
| Founded | 1997 | 1897 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Power Generation | Medical/Dental Instruments |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 41.9B | 43.0B |
| IPO Year | 2005 | 1998 |
| Metric | WCN | BDX |
|---|---|---|
| Price | $166.04 | $182.79 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 19 | 13 |
| Target Price | ★ $204.21 | $186.00 |
| AVG Volume (30 Days) | 1.2M | ★ 1.8M |
| Earning Date | 04-22-2026 | 05-07-2026 |
| Dividend Yield | 0.85% | ★ 2.89% |
| EPS Growth | ★ 74.48 | N/A |
| EPS | ★ 2.02 | 1.59 |
| Revenue | $9,466,915,000.00 | ★ $21,840,000,000.00 |
| Revenue This Year | $6.14 | N/A |
| Revenue Next Year | $6.18 | $3.02 |
| P/E Ratio | ★ $81.95 | $114.44 |
| Revenue Growth | 6.14 | ★ 8.24 |
| 52 Week Low | $146.89 | $140.11 |
| 52 Week High | $188.75 | $213.08 |
| Indicator | WCN | BDX |
|---|---|---|
| Relative Strength Index (RSI) | 48.06 | 74.48 |
| Support Level | $163.44 | $163.44 |
| Resistance Level | $172.17 | $187.35 |
| Average True Range (ATR) | 3.64 | 4.34 |
| MACD | -0.51 | 1.30 |
| Stochastic Oscillator | 30.75 | 91.48 |
Waste Connections is a North American waste management company focused on integrated waste collection services. The firm primarily focuses on residential, commercial, municipal, and industrial waste collection, with a secondary market focus on rural areas. With 113 landfills and 222 transfer stations as of 2024, it is the third-largest waste management company by revenue. Revenue is split among six operating segments: Western, Southern, Eastern, Central, Canada, and Midsouth.
Becton Dickinson operates in four business units. Medical essentials (35% of total sales) includes the legacy medical surgical unit, which sells catheters, syringes, and infection prevention products. Connected care (24%) core products include the Alaris infusion pump, Pyxis dispensing system, and pharmacy automation platforms. Biopharma systems (13%) produces prefillable syringes and autoinjectors. Interventional (29%) is composed of the surgery, peripheral vascular, and urology segments. More than 60% of revenue comes from the United States.